Developer docs
API playgroundTry for free, no card

Search company profiles

Palatin Technologies

Full company profile

uuid0003opi

Namestring
Palatin Technologies
Legal namestring
Palatin Technologies, Inc.
Websiteurl
palatin.com
Company typeenum
Public
Founded yearint
1996
Descriptiontext

Palatin Technologies is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Princeton, New Jersey (Nasdaq: PTN, transferring from NYSE American on May 29, 2026). The company develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system, with a primary strategic focus on MC4R-selective agonists for obesity — particularly rare neuroendocrine disorders including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, where no approved pharmacologic treatments currently exist. Its lead candidates include PL7737, an oral MC4R agonist, and next-generation once-weekly injectable peptide MC4R agonists.

The company operates a five-receptor MCR agonist platform (MC1R–MC5R) that has produced a diversified pipeline: PL9643 (MC1R, dry eye disease — Phase 3, sublicensed to Altanispac Labs in January 2026), PL8177 (oral MC1R, ulcerative colitis — positive Phase 2 topline), PL9654 (MC1R, retinal diseases — licensed to Boehringer Ingelheim under a deal worth up to €280 million in milestones), and PL9588 (glaucoma, preclinical). Earlier asset Vyleesi (bremelanotide, HSDD) was divested to Cosette Pharmaceuticals in December 2023.

Palatin's business model is asset-light and partnership-driven: it monetizes its pipeline through licensing deals, milestone payments, and royalties rather than direct commercialization, while raising operating capital through registered direct and public equity offerings and New Jersey non-dilutive NOL funding. Following the Vyleesi divestiture, revenue has shifted to collaboration/license income, with Q3 FY2026 recording $3.9M from the Altanispac sublicensing and the Boehringer deal providing both upfront and milestone receipts. Cash and equivalents of $10.2M as of March 31, 2026 are projected to fund operations through June 2027, with the company returning to significantly narrowed net losses ($1.4M in Q3 FY2026 versus $4.8M prior year).

Short descriptiontext

Palatin Technologies is a clinical-stage biopharmaceutical company developing melanocortin receptor-targeted therapeutics, with its primary focus on MC4R agonists for rare obesity disorders and additional programs in dry eye, ulcerative colitis, retinal disease, and glaucoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
melanocortin receptor therapeutics, rare obesity drug development, ophthalmic peptide therapeutics, inflammatory bowel disease drugs, biopharmaceutical licensing partnerships
Industry2 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Collaboration and License Revenue
TypeLicensing Royalties
Description

Revenue from strategic partnerships including Boehringer Ingelheim retinal disease collaboration and Altanispac Labs PL9643 sublicensing. Includes upfront payments, research milestones, development milestones, regulatory milestones, commercial milestones, and tiered royalties on net sales.

palatin.com
2Public Offerings
TypeOne Time License
Description

Capital raised through registered direct offerings and public offerings of common stock and warrants to healthcare-focused institutional investors. Proceeds used for general corporate purposes and development of obesity program.

prnewswire.com
3Non-Dilutive Funding (NOL Program)
TypeData Monetisation
Description

New Jersey's Net Operating Loss program allowing biotech companies to sell net operating losses for cash. Received approximately $4.7 million in January 2023, with total non-dilutive funding under this program of about $18 million.

prnewswire.com
4Asset Sale (Vyleesi)
TypeOne Time License
Description

Sale of Vyleesi worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million (December 2023).

palatin.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Vyleesi
Description

FDA-approved treatment for hypoactive sexual desire disorder (HSDD), sold to Cosette Pharmaceuticals in December 2023.

palatin.com
Core offering1 text field

Palatin Technologies is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system. Its pipeline includes MC4R agonists for rare neuroendocrine obesity disorders (PL7737 and next-generation peptides), MC1R agonists for dry eye disease (PL9643), ulcerative colitis (PL8177), and retinal diseases (PL9654), plus a topical MCR agonist for glaucoma (PL9588). The company commercializes assets primarily through licensing and collaboration agreements with larger pharmaceutical partners rather than direct sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 3 MELODY-1 trial: 6 of 13 symptom endpoints showed statistically significant complete symptom resolution with PL9643 vs placebo (p<0.05)
+3 more records
Product overview1 text field

Palatin Technologies is a biopharmaceutical company developing first-in-class medicines based on melanocortin receptor modulation. The company's primary focus is on MC4R-based obesity programs targeting rare neuroendocrine disorders (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome), with PL7737 as an oral small molecule candidate and next-generation peptide agonists for once-weekly injection. The portfolio includes PL9643 for dry eye disease (Phase 3, sublicensed to Altanispac Labs), PL8177 for ulcerative colitis (Phase 2), PL9654 for retinal diseases (licensed to Boehringer Ingelheim), and PL9588 for glaucoma. The company leverages a proprietary MCR agonist platform with receptor-selective design capabilities.

Product and service1 record
1PL7737
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Altanispac Labs
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Sublicensing agreement for MC1R agonist PL9643 for dry eye disease treatment. Palatin received $3.8 million in upfront consideration in January 2026, eligible for additional future payments including asset disposition and commercialization milestones, as well as royalties on net sales. Agreement sharpens focus on core obesity portfolio while preserving upside.

palatin.com
2Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-18
Description

Global research collaboration and licensing agreement to develop first-in-class melanocortin receptor-targeted treatments for patients with retinal diseases including diabetic retinopathy and diabetic macular edema. Palatin received €2.0 million upfront and €5.5 million research milestone, eligible for up to €278 million in additional milestones plus tiered royalties on net sales. Boehringer focuses on addressing three main drivers of retinal disease: inflammation, vascular dysfunction, and neurodegeneration.

palatin.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-12-01
Description

Sale of Vyleesi worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million. Transaction completed in December 2023, with Palatin no longer recording product sales to pharmacy distributors.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Rhythm Pharmaceuticals develops MC4R agonists (setmelanotide) for rare genetic obesity disorders including Bardet-Biedl syndrome and POMC deficiency—the same MC4R pathway Palatin targets. Most directly comparable peer in melanocortin biology for rare obesity.

TypeDirect peer
Description

Soleno Therapeutics develops diazoxide choline extended-release (DCCR) for Prader-Willi syndrome, directly overlapping with one of Palatin's primary target indications. Same rare disease focus and orphan drug strategy.

TypeDirect peer
Description

Crinetics develops peptide therapeutics targeting endocrine GPCRs for rare endocrine disorders including acromegaly and congenital hyperinsulinism. Comparable small-cap clinical-stage peptide platform company with similar disease-area focus.

TypeDirect peer
Description

Lexicon Pharmaceuticals is a small-cap clinical-stage biotech focused on endocrine and metabolic disorders. Similar size, public listing, and rare disease specialty pharma positioning.

TypeDirect peer
Description

Aldeyra develops novel therapeutics for ocular inflammation (dry eye disease and allergic conjunctivitis), directly comparable to Palatin's PL9643 dry eye program. Similar small-cap clinical-stage ophthalmic biotech.

TypeBroad incumbent
Description

Madrigal develops resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis (MASH). Larger specialty pharma in metabolic disease space with approved product, providing peer benchmark for commercialization in metabolic indications.

TypeEmerging player
Description

Structure Therapeutics develops oral peptide and small molecule GLP-1R agonists for obesity and metabolic disorders. Represents the broader competitive landscape in obesity therapeutics, with oral peptide platform approach similar to Palatin's oral MC4R strategy.

TypeBroad incumbent
Description

Zealand Pharma develops peptide-based therapeutics for metabolic diseases including obesity. Larger European-listed peptide platform company providing benchmark for peptide therapeutic development in metabolic space.

TypeDirect peer
Description

BioLineRx is a clinical-stage biopharmaceutical company developing novel peptide therapeutics for hematological and inflammatory diseases. Comparable size, business model, and partnership-driven revenue profile.

TypeDirect peer
Description

Tempest Therapeutics is a small-cap clinical-stage biotech with similar financing profile (multiple registered direct offerings, reverse stock considerations, partnership-dependent revenue). Comparable small-cap biotech peer structure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Palatin Technologies

Biopharmaceutical Therapeuticspalatin.com

Palatin Technologies is a clinical-stage biopharmaceutical company developing melanocortin receptor-targeted therapeutics, with its primary focus on MC4R agonists for rare obesity disorders and additional programs in dry eye, ulcerative colitis, retinal disease, and glaucoma.

What Palatin Technologies does

Palatin Technologies is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Princeton, New Jersey (Nasdaq: PTN, transferring from NYSE American on May 29, 2026). The company develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system, with a primary strategic focus on MC4R-selective agonists for obesity — particularly rare neuroendocrine disorders including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, where no approved pharmacologic treatments currently exist. Its lead candidates include PL7737, an oral MC4R agonist, and next-generation once-weekly injectable peptide MC4R agonists.

The company operates a five-receptor MCR agonist platform (MC1R–MC5R) that has produced a diversified pipeline: PL9643 (MC1R, dry eye disease — Phase 3, sublicensed to Altanispac Labs in January 2026), PL8177 (oral MC1R, ulcerative colitis — positive Phase 2 topline), PL9654 (MC1R, retinal diseases — licensed to Boehringer Ingelheim under a deal worth up to €280 million in milestones), and PL9588 (glaucoma, preclinical). Earlier asset Vyleesi (bremelanotide, HSDD) was divested to Cosette Pharmaceuticals in December 2023.

Palatin's business model is asset-light and partnership-driven: it monetizes its pipeline through licensing deals, milestone payments, and royalties rather than direct commercialization, while raising operating capital through registered direct and public equity offerings and New Jersey non-dilutive NOL funding. Following the Vyleesi divestiture, revenue has shifted to collaboration/license income, with Q3 FY2026 recording $3.9M from the Altanispac sublicensing and the Boehringer deal providing both upfront and milestone receipts. Cash and equivalents of $10.2M as of March 31, 2026 are projected to fund operations through June 2027, with the company returning to significantly narrowed net losses ($1.4M in Q3 FY2026 versus $4.8M prior year).

Palatin Technologies firmographics

Firmographics
Name
Palatin Technologies
Legal name
Palatin Technologies, Inc.
Website
https://palatin.com
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
Palatin Technologies is a clinical-stage biopharmaceutical company developing melanocortin receptor-targeted therapeutics, with its primary focus on MC4R agonists for rare obesity disorders and additional programs in dry eye, ulcerative colitis, retinal disease, and glaucoma.
Ownership category
akta.pro rank

Palatin Technologies industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Melanocortin receptor therapeutics
  • Rare obesity drug development
  • Ophthalmic peptide therapeutics
  • Inflammatory bowel disease drugs
  • Biopharmaceutical licensing partnerships

Where Palatin Technologies is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Palatin Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Collaboration and License Revenue: Revenue from strategic partnerships including Boehringer Ingelheim retinal disease collaboration and Altanispac Labs PL9643 sublicensing. Includes upfront payments, research milestones, development milestones, regulatory milestones, commercial milestones, and tiered royalties on net sales.
  2. Public Offerings: Capital raised through registered direct offerings and public offerings of common stock and warrants to healthcare-focused institutional investors. Proceeds used for general corporate purposes and development of obesity program.
  3. Non-Dilutive Funding (NOL Program): New Jersey's Net Operating Loss program allowing biotech companies to sell net operating losses for cash. Received approximately $4.7 million in January 2023, with total non-dilutive funding under this program of about $18 million.
  4. Asset Sale (Vyleesi): Sale of Vyleesi worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million (December 2023).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Palatin Technologies product offering

Product offering

Core offering

Palatin Technologies is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system. Its pipeline includes MC4R agonists for rare neuroendocrine obesity disorders (PL7737 and next-generation peptides), MC1R agonists for dry eye disease (PL9643), ulcerative colitis (PL8177), and retinal diseases (PL9654), plus a topical MCR agonist for glaucoma (PL9588). The company commercializes assets primarily through licensing and collaboration agreements with larger pharmaceutical partners rather than direct sales.

Product overview

Palatin Technologies is a biopharmaceutical company developing first-in-class medicines based on melanocortin receptor modulation. The company's primary focus is on MC4R-based obesity programs targeting rare neuroendocrine disorders (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome), with PL7737 as an oral small molecule candidate and next-generation peptide agonists for once-weekly injection. The portfolio includes PL9643 for dry eye disease (Phase 3, sublicensed to Altanispac Labs), PL8177 for ulcerative colitis (Phase 2), PL9654 for retinal diseases (licensed to Boehringer Ingelheim), and PL9588 for glaucoma. The company leverages a proprietary MCR agonist platform with receptor-selective design capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Vyleesi: FDA-approved treatment for hypoactive sexual desire disorder (HSDD), sold to Cosette Pharmaceuticals in December 2023.

Products and services

  • PL7737

Quantifiable outcome

  • Phase 3 MELODY-1 trial: 6 of 13 symptom endpoints showed statistically significant complete symptom resolution with PL9643 vs placebo (p<0.05)
  • +3 more outcomes

Companies that use Palatin Technologies

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Palatin Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Palatin Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Altanispac LabscoreStrategic or Co-development Partner · 1 January 2026Sublicensing agreement for MC1R agonist PL9643 for dry eye disease treatment. Palatin received $3.8 million in upfront consideration in January 2026, eligible for additional future payments including asset disposition and commercialization milestones, as well as royalties on net sales. Agreement sharpens focus on core obesity portfolio while preserving upside.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 18 August 2025Global research collaboration and licensing agreement to develop first-in-class melanocortin receptor-targeted treatments for patients with retinal diseases including diabetic retinopathy and diabetic macular edema. Palatin received €2.0 million upfront and €5.5 million research milestone, eligible for up to €278 million in additional milestones plus tiered royalties on net sales. Boehringer focuses on addressing three main drivers of retinal disease: inflammation, vascular dysfunction, and neurodegeneration.
  • Cosette PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 1 December 2023Sale of Vyleesi worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million. Transaction completed in December 2023, with Palatin no longer recording product sales to pharmacy distributors.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Palatin Technologies competitors and assessment

Company assessment

Direct peers

  • Rhythm Pharmaceuticals: Rhythm Pharmaceuticals develops MC4R agonists (setmelanotide) for rare genetic obesity disorders including Bardet-Biedl syndrome and POMC deficiency—the same MC4R pathway Palatin targets. Most directly comparable peer in melanocortin biology for rare obesity.
  • Soleno Therapeutics: Soleno Therapeutics develops diazoxide choline extended-release (DCCR) for Prader-Willi syndrome, directly overlapping with one of Palatin's primary target indications. Same rare disease focus and orphan drug strategy.
  • Crinetics Pharmaceuticals: Crinetics develops peptide therapeutics targeting endocrine GPCRs for rare endocrine disorders including acromegaly and congenital hyperinsulinism. Comparable small-cap clinical-stage peptide platform company with similar disease-area focus.
  • Lexicon Pharmaceuticals: Lexicon Pharmaceuticals is a small-cap clinical-stage biotech focused on endocrine and metabolic disorders. Similar size, public listing, and rare disease specialty pharma positioning.
  • Aldeyra Therapeutics: Aldeyra develops novel therapeutics for ocular inflammation (dry eye disease and allergic conjunctivitis), directly comparable to Palatin's PL9643 dry eye program. Similar small-cap clinical-stage ophthalmic biotech.
  • BioLineRx: BioLineRx is a clinical-stage biopharmaceutical company developing novel peptide therapeutics for hematological and inflammatory diseases. Comparable size, business model, and partnership-driven revenue profile.
  • Tempest Therapeutics: Tempest Therapeutics is a small-cap clinical-stage biotech with similar financing profile (multiple registered direct offerings, reverse stock considerations, partnership-dependent revenue). Comparable small-cap biotech peer structure.

Broad incumbents

  • Madrigal Pharmaceuticals: Madrigal develops resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis (MASH). Larger specialty pharma in metabolic disease space with approved product, providing peer benchmark for commercialization in metabolic indications.
  • Zealand Pharma: Zealand Pharma develops peptide-based therapeutics for metabolic diseases including obesity. Larger European-listed peptide platform company providing benchmark for peptide therapeutic development in metabolic space.

Emerging players

  • Structure Therapeutics: Structure Therapeutics develops oral peptide and small molecule GLP-1R agonists for obesity and metabolic disorders. Represents the broader competitive landscape in obesity therapeutics, with oral peptide platform approach similar to Palatin's oral MC4R strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Palatin Technologies social profiles

Digital presence

Palatin Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Palatin Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Palatin Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Palatin Technologies funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Palatin Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Palatin Technologies

What does Palatin Technologies do?

Palatin Technologies is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system. Its pipeline includes MC4R agonists for rare neuroendocrine obesity disorders (PL7737 and next-generation peptides), MC1R agonists for dry eye disease (PL9643), ulcerative colitis (PL8177), and retinal diseases (PL9654), plus a topical MCR agonist for glaucoma (PL9588). The company commercializes assets primarily through licensing and collaboration agreements with larger pharmaceutical partners rather than direct sales.

Is Palatin Technologies a public or private company?

Palatin Technologies is a public company. It is classified as public and is currently operating.

When was Palatin Technologies founded?

Palatin Technologies was founded in 1996. It employs 11 to 50 people.

Where is Palatin Technologies based?

Palatin Technologies is headquartered in Princeton, United States, in the North America region.

How does Palatin Technologies make money?

Four revenue lines are on record. Collaboration and License Revenue is the primary driver. The others are public Offerings, non-Dilutive Funding (NOL Program) and asset Sale (Vyleesi).

Who are Palatin Technologies's main competitors?

Direct peers on record are Rhythm Pharmaceuticals, Soleno Therapeutics, Crinetics Pharmaceuticals, Lexicon Pharmaceuticals, Aldeyra Therapeutics, BioLineRx and Tempest Therapeutics. Broad incumbents are Madrigal Pharmaceuticals and Zealand Pharma. Structure Therapeutics is listed as an emerging player.

Does Palatin Technologies have an API?

No public API is recorded for Palatin Technologies.

What industry is Palatin Technologies in?

Palatin Technologies's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolPalatin (PTN) Q1 2027 Earnings Call TranscriptPalatin reported Q1 2027 revenue of $362,000 and a net loss of $5.1 million, with R&D spending of $3.4 million. The company targets Phase I initiation of its lead lipidated MC4R peptide in the first half of 2027, with clinical data expected in the second half.The Motley FoolPalatin (PTN) Q1 2027 Earnings Call TranscriptPalatin reported Q1 2027 revenue of $362,000 and a net loss of $5.1 million, with R&D spending of $3.4 million. The company targets Phase I initiation of its lead lipidated MC4R peptide in H1 2027 and oral small molecule Phase I in H2 2027. It holds $3.7 million in cash and is evaluating financing alternatives.Seeking AlphaPalatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptidePalatin Technologies said in its Q1 fiscal 2027 earnings call that it prioritized advancing its next-generation MC4R programs, including IND-enabling activities for its lead lipidated peptide and oral small-molecule candidates. The company targeted a phase I start in the first half of calendar 2027 for the lead MC4R lipidated peptide.Seeking AlphaPalatin Technologies, Inc. (PTN) Q1 2027 Earnings Call TranscriptPalatin Technologies reported its fiscal Q1 2027 results for the quarter ended September 30, 2026, with CEO Carl Spana and CFO Steve Wills leading the call. The transcript covers financial results and operating priorities, but no specific figures or guidance were disclosed in the provided excerpt.TradingViewPTN: Higher MC4R investment advances 2027 clinical milestones, but additional financing is essentialPalatin Technologies reported Q1 FY27 revenue of $362,000, down from prior-year figures that included upfront milestones, while MC4R R&D spending increased. The company targets PL2000 Phase I for H1 2027, but additional financing remains essential and transaction timing is uncertain.Investing.comEarnings call transcript: Palatin Technologies Q1 2026 misses as stock falls 14%Palatin Technologies reported a Q1 2027 net loss of $5.1 million, with revenue of $3 million and a $1.29 EPS loss, missing the $4.26 forecast. Collaboration and license revenue fell 95.9% to $362,000, and shares dropped 14.1% to $5.26. The company targets an IND filing in Q2 2027 and Phase I in H2 2027.TradingViewPalatin Technologies Q1 2027 Earnings Call Is LivePalatin Technologies' Q1 2027 earnings call is live, with executives set to discuss financial results and answer analyst questions. Management commentary on demand, margins, or capital spending could move markets.Stock TitanPalatin to report Q1 FY2027 results Nov. 17Palatin Technologies will report its first quarter fiscal year 2027 operating results on November 17, 2026, before U.S. markets open. The company will also host a conference call and live audio webcast at 11:00 a.m. ET that day, including an update on corporate and development activities.Business & FinancialPalatin's Peptide Is Advancing Toward The Clinic As Big Pharma Pays Billions For Early Peptides (NASDAQ: PTN)Palatin Technologies is preparing its next-generation MC4R peptide for first human testing in 2027. Gilead's $1.275 billion upfront commitment for a Phase 1 peptide signals big pharma's willingness to pay early. Palatin's trial would be its first human data for a next-generation MC4R-selective peptide.American Banking and Market NewsPalatin Technologies (PTN) Expected to Announce Quarterly Earnings on FridayPalatin Technologies is expected to report Q1 2027 earnings on Friday, November 13th, with analysts projecting a loss of $0.42 per share and revenue of $2.51 million. The company's last earnings beat estimates, posting a loss of $1.11 per share versus a $1.20 consensus and revenue of $0.30 million versus $1.50 million estimates.